Spyre Therapeutics (SYRE) Preferred Shares (2015 - 2026)

Spyre Therapeutics has reported Preferred Shares for 4 years, with the latest figure at $9.4 million in Q1 2026.

• For the quarter ending Q1 2026, Preferred Shares changed N/A year-over-year to $9.4 million; the trailing twelve-month figure through Mar 2026 stood at $9.4 million (changed N/A YoY), and the FY2025 full-year result was $146.4 million, up 1458.54% from the prior year.
• Preferred Shares for Q1 2026 stood at $9.4 million, down from $146.4 million in the prior quarter.
• The five-year high for Preferred Shares was $184.9 million in Q1 2024, with the low at $9.4 million in Q4 2024.
• Historically, Preferred Shares has averaged $107.2 million across 3 years, with a median of $146.4 million in 2024.
• The largest YoY upside for Preferred Shares was 1458.54% in 2025 against a maximum downside of 1458.54% in 2025.
• Spyre Therapeutics' Preferred Shares stood at $9.4 million in 2024, then jumped by 1458.54% to $146.4 million in 2025, then tumbled by 93.58% to $9.4 million in 2026.
• The last three Preferred Shares figures came in at $9.4 million (Q1 2026), $146.4 million (Q4 2025), and $9.4 million (Q4 2024), per Business Quant data.